ASX RELEASE

Sienna announces intention to lodge court orders with ASIC

- Virtual Scheme Meeting to be held at 11.00 am (Melbourne time) on 15 July 2020

Melbourne, Australia, 10 June 2020: Sienna Cancer Diagnostics (ASX: SDX) ("Sienna" or "the Company") is pleased to announce that the Federal Court of Australia has today made orders approving the dispatch of an explanatory statement (**Scheme Booklet**) in relation to the proposed acquisition of all the shares in Sienna by BARD1 Life Sciences Limited by way of a scheme of arrangement (**Scheme**) as announced on 8 April 2020.

The Federal Court of Australia also made an order for the virtual Scheme Meeting to be held at **11.00 am (Melbourne time) on 15 July 2020**, using the website specified in the Notice of Meeting and without Sienna Shareholders being physically present in the same place.

The Scheme Booklet containing details of the Scheme, the Independent Expert's Report and the Notice of Meeting convening the Scheme Meeting will be released in a further announcement following the registration of the Scheme Booklet by the Australian Securities and Investments Commission.

ENDS.

For Further Information, please contact:
Carl Stubbings, CEO & Managing Director
Sienna Cancer Diagnostics Ltd
cstubbings@siennadiagnostics.com.au
+61 3 8288 2141

The release of this announcement was authorised by Tony Di Pietro, Company Secretary.

About Sienna Cancer Diagnostics Ltd.
Sienna is a medical technology company that develops and commercialises diagnostic tests to assist in the early and accurate diagnosis of cancer, enabling improved treatment and patient outcomes. Sienna's first product, hTERT, a test that aids in the diagnosis of bladder cancer, has been launched and is being commercialised through a growing network of distribution partners globally.

Sienna entered the global liquid biopsy market in 2019 via the strategic acquisition of a "Molecular Net" technology called SIEN-NET™. The first commercial embodiment of SIEN-NET is EXO-NET™, which has been specifically designed to purify a patient sample for cancer-associated exosomes.

The Company recently announced the signing of an exclusive worldwide licence agreement with the University of Adelaide to develop and commercialise a unique cancer probe, SubB2M, which binds to a unique sugar molecule only present in human cancers and can detect its presence in the serum of cancer patients. SubB2M has the potential to detect cancer in a range of testing modalities such as liquid biopsies, immunoassays, circulating tumor cell assays and PET imaging.